en ENGLISH
eISSN: 2300-8660
ISSN: 0031-3939
Pediatria Polska - Polish Journal of Paediatrics
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Kontakt Zasady publikacji prac Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
SCImago Journal & Country Rank
4/2023
vol. 98
 
Poleć ten artykuł:
Udostępnij:
streszczenie artykułu:
Artykuł przeglądowy

Pulmonary inflammatory myofibroblastic tumor in children

Maria Wawszczak
1
,
Grażyna Kraj
2
,
Joanna Lange
1
,
Renata Langfort
3

  1. Department of Paediatric Pneumonology and Allergology, Medical University of Warsaw, Warsaw, Poland
  2. Department of Pediatric, Mazovian Centre for the Treatment of Lung Diseases and Tuberculosis in Otwock, Otwock, Poland
  3. Department of Pathology, National Tuberculosis and Lung Diseases, Research Institute, Warsaw, Poland
Pediatr Pol 2023; 98 (4): 320-325
Data publikacji online: 2023/12/15
Pełna treść artykułu Pobierz cytowanie
 
Metryki PlumX:


Inflammatory myofibroblastic tumor (IMT) is a rare neoplasm characterized by mesenchymal spindle cell proliferation with a marked inflammatory infiltrate component. Although the exact etiopathology of pulmonary IMT is still not clear, gene fusions involving anaplastic lymphoma kinase (ALK) or ROS proto-oncogene 1, receptor tyrosine kinase (ROS1), neurotrophic tyrosine receptor kinase (NTRK), platelet-derived growth factor receptor (PDGFR) and rearranged during transfection (RET) have been recently detected in immunohistochemical assessment of this lesion. Due to its nonspecific clinical or radiological presentation, the diagnosis of IMT primarily depends on histopathological findings. Surgery remains the mainstay of treatment and provides the best chance to limit recurrence. In unresectable lesions or multifocal/metastatic disease, treatment with chemotherapy or ALK, ROS1, RET and NTRK inhibitors is recommended. The prognosis in children with IMT is generally perceived as favorable, although local invasion and metastasis have been reported.
 
© 2024 Termedia Sp. z o.o.
Developed by Bentus.